|

CLICK
BELOW TO DOWNLOAD A PDF OF THE MONOGRAPH.
Click on the thumbnail to open and print the PDF file, or, to download
and save the file to your desktop, please "right click"
on the thumbnail and select "Save Target As..."

Featuring
John Betteridge, MD, PhD
London, England
Ralph A. DeFronzo, MD
San Antonio, Texas
Ele Ferrannini, MD
Pisa, Italy
Michael Nauck, MD, PhD
Bad Lauterberg, Germany
|
|

An in-depth CME/CE Monograph based
on the symposium given at the American Diabetes Association's
67th Scientific Sessions, Sunday, June 24, 2007
Release Date: February 2008
Expiration Date: February 28, 2009
To reserve your FREE copy of the monograph,
call 800-260-4378, extension 315, or
CLICK
HERE to download the simple request form.
You may also download a PDF of the monograph by clicking
the thumbnail on the left side of this screen.

Since oral antidiabetic agents were first used in the 1950s,
new classes of agents and refinements within the classes have
provided a wider array of treatment options for diabetes.
Despite treatment advances, diabetes continues to be poorly
controlled for many patients. A recent flurry of research
has advanced our understanding of diabetes pathogenesis and
highlighted the novel approaches that may better limit glucose
toxicity and potentially minimize the long-term outcomes of
the disease. Advances in the understanding of diabetes pathogenesis
and new ways of managing the disease from a mechanistic point
of view will be reviewed.
The target audience for this monograph is diabetologists and
other clinicians including physicians, nurses, pharmacists,
dietitians, psychologists, and podiatrists with expertise
in diabetes.

Upon completion of this program, participants should be able
to:
• Explain the long-term consequences of poor glucose
control in type 2 diabetes mellitus (DM)
• Describe beta-cell failure and its effect on the progression
of type 2 DM
• Identify new or emerging pharmacotherapeutic options
and how their novel mechanisms may be useful in treating type
2 DM

The Center for Health Care Education, LLC (CHCE), is accredited
by the Accreditation Council for Continuing Medical Education
to provide continuing medical education for physicians.

CHCE designates this educational activity for a maximum of
2.0 AMA PRA Category 1 Credit(s)™. Physicians
should only claim credit commensurate with the extent of their
participation in the activity.
This continuing nursing education activity is
approved by CHCE for 2.4 Contact Hours (CHs). CHCE is an Approved
Provider of continuing nursing education by the North Carolina
Nurses Association, an accredited approver by the American
Nurses Credentialing Center's Commission on Accreditation.
To receive credit, participants must
read through the monograph, complete the posttest and evaluation
form, and submit to CHCE before the expiration date.
|
| |
|
|